BridgeBio to seek approval of limb-girdle drug following new study data

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle stability that one executive described as a “home run.”

By Ben Fidler • Oct. 27, 2025

Hemab collects another $157M to go after ‘underserved’ blood diseases

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation disorders company,” its CEO said. 

By Ben Fidler • Oct. 27, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

Biogen licenses a possible immune drug from OrbiMed-backed biotech

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

By Jacob Bell • Oct. 24, 2025

Ventyx shares soar after study suggests cardiovascular benefits for experimental drug

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

By Kristin Jensen • Oct. 23, 2025

Moderna says CMV vaccine once seen as future blockbuster fails key study

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, heightening pressure on Moderna’s flagging respiratory vaccine business.

By Delilah Alvarado • Oct. 22, 2025

Electra nabs $183M for its rare disease drug ambitions

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare inflammatory condition.

By Gwendolyn Wu • Oct. 22, 2025

Flagship bets again on AI with Expedition

The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech that already has a partnership with Pfizer.

By Gwendolyn Wu • Oct. 22, 2025

Iambic partners with Jazz; Merck breaks ground on $3B plant

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

By BioPharma Dive staff • Oct. 21, 2025

Galapagos to wind down cell therapy business after failed attempt at sale

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain acquisition offers as it works to close the unit.

By Kristin Jensen • Oct. 21, 2025

Alto shares double on plans to speed depression drug’s development

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.

By Jacob Bell • Oct. 20, 2025

Summit’s dual-acting drug scores lung cancer win

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.

By Jonathan Gardner • Oct. 20, 2025

I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy

I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.

By BioPharma Dive staff • Oct. 17, 2025

A longshot bet on a tremor drug pays off

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive data from a pair of late-stage clinical trials.

By Jacob Bell • Oct. 16, 2025

A regenerative therapy for hair loss attracts a mega-fundraising round

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to activate dormant hair follicle stem cells.

By Jacob Bell • Oct. 15, 2025

[Podcast] The Progress Profile: Alzheimer’s Research in Focus

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

By BioPharma Dive's studioID • Oct. 15, 2025

Cancer drug startup Tubulis raises $361 million for ADCs

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that’s currently in early-stage testing.

By Gwendolyn Wu • Oct. 15, 2025

AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell therapy division and an investor wants Novavax to sell itself.

By BioPharma Dive staff • Oct. 14, 2025

Kailera nets $600M more to advance Zepbound-like obesity drug

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

By Jonathan Gardner • Oct. 14, 2025

BioCryst goes ‘all in’ on rare swelling disease with Astria deal

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.

By Delilah Alvarado • Oct. 14, 2025

A young biotech nets $70M for a new type of allergy drug

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company says could lead to faster and more complete disease control.

By Gwendolyn Wu • Oct. 13, 2025

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.

By Jacob Bell • Oct. 12, 2025

AstraZeneca ups investment in Virginia; Moderna vets launch VC fund

The British pharma is adding $500 million, and ADC production capabilities, to a planned Virginia facility. Elsewhere, Ferring announced layoffs and Sanofi touted a radiopharmaceutical drug.

By BioPharma Dive staff • Oct. 10, 2025

Evommune files for IPO to advance immune drug work

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for chronic skin hives.

By Gwendolyn Wu • Oct. 10, 2025

Regeneron, needing a turnaround, gains new use for cancer drug

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.

By Kristin Jensen • Oct. 9, 2025

Arthrosi snags $153M in pursuit of a new gout drug

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve upon existing therapies. 

By Ben Fidler • Oct. 8, 2025